Detalles de la búsqueda
1.
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]. / Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper).
Nervenarzt
; 92(8): 773-801, 2021 Aug.
Artículo
en Alemán
| MEDLINE | ID: mdl-34297142
2.
REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program.
Neurol Ther
; 2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38530606
3.
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4.
Expert Opin Pharmacother
; 23(13): 1503-1510, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35930260
4.
Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status.
Ther Adv Neurol Disord
; 14: 17562864211005588, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34046085
5.
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Ther Adv Neurol Disord
; 14: 17562864211039648, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34422112
6.
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Expert Opin Pharmacother
; 21(16): 1965-1969, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32658554
7.
Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study.
Ther Adv Neurol Disord
; 12: 1756286419835077, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30944584
8.
An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM).
Ther Adv Neurol Disord
; 11: 1756285617749802, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29399053
9.
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
J Neurol
; 265(7): 1521-1527, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29696498
10.
Characteristic gene expression profile of primary human cerebral endothelial cells.
FASEB J
; 16(6): 589-91, 2002 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-11919163
11.
Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model.
Ther Adv Neurol Disord
; 8(1): 3-13, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25584069
12.
Adherence to, and effectiveness of, subcutaneous interferon ß-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Expert Opin Drug Deliv
; 12(8): 1239-50, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26098143
13.
Inflammation in multiple sclerosis: the good, the bad, and the complex.
Lancet Neurol
; 1(8): 499-509, 2002 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-12849335
14.
Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-up study.
J Neurol
; 251(1): 30-4, 2004 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-14999486
15.
Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
Acta Neuropathol Commun
; 4(1): 81, 2016 08 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27503238
16.
UM 9(5)h and UM 9(5)p, human and porcine noncoding transcripts with preferential expression in the cerebellum.
RNA
; 8(12): 1538-47, 2002 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-12515386
Resultados
1 -
16
de 16
1
Próxima >
>>